psychedelic therapeutics Archives

How Clearmind Medicine is positioning CMND-100 within the emerging non-hallucinogenic neuroplastogen market

By Soujanya Ravi on May 26, 2026 Pharma & Biotech

Clearmind Medicine is advancing CMND-100 in Alcohol Use Disorder. Discover why the non-hallucinogenic neuroplastogen market is gaining attention.

How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics

By Soujanya Ravi on May 20, 2026 Features & Analysis

Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.

Why Psyence Biomedical Ltd.’s Australian trial strategy could shape global psychedelic drug development pathways

By Soujanya Ravi on April 23, 2026 Pharma & Biotech

Psyence Biomedical Ltd. advances NPX-5 dosing in Australia. Discover how this trial strategy could shape global psychedelic drug development.

How subcutaneous amivantamab approval in Europe could reshape EGFR-mutated NSCLC treatment workflows

By Soujanya Ravi on February 23, 2026 Pharma & Biotech

EU approves subcutaneous amivantamab for expanded EGFR lung cancer dosing. Discover what this changes for clinicians and health systems.

Can PharmAla’s three year stability program de risk MDMA distribution challenges?

By Soujanya Ravi on February 23, 2026 Pharma & Biotech

PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.

Why Compass Pathways’ upcoming COMP360 data could redefine late-stage psychedelic drug development

By Pallavi Madhiraju on February 17, 2026 Pharma & Biotech

Compass Pathways is set to release pivotal Phase 3 COMP360 data in treatment-resistant depression. Find out why this readout could reshape psychedelic drug development.